Ceralasertib is an oral selective inhibitor of the ATR kinase, an important DNA-repairing protein in tumor cells.

The Food and Drug Administration (FDA) has approved Myqorzo™ (aficamten) for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and ...

Lunsumio Velo is supplied as a ready-to-use, preservative-free solution in single-dose vials containing 5mg/0.5mL and 45mg/mL.

Veligrotug, an IGF-1R inhibitor, is under FDA Priority Review for thyroid eye disease based on positive phase 3 trial data.

(HealthDay News) — The US Food and Drug Administration (FDA) is weighing a change that could make warning labels on dietary supplements appear less often on packaging. Unlike prescription drugs, ...

Vaccination linked to lower risk for hospitalization, critical care unit admission, preterm birth during delta and omicron periods ...

According to Lilly, a New Drug Application for orforglipron for the treatment of adults with obesity or overweight has been submitted to the Food and Drug Administration.

Fesilty is supplied as a lyophilized powder for reconstitution in a single-dose vial containing approximately 1g of human fibrinogen.

Bisphosphonates may reduce pain intensity in short term, but may result in little to no difference in immediate and medium term.

Dr Dana Rizk is Professor of Medicine in the Division of Nephrology at the University of Alabama at Birmingham (UAB) and a VOYXACT VISIONARY Study Investigator and Co-Chair of the Steering Committee.

HealthDay News — The US Food and Drug Administration (FDA) approved a new safety warning for Depo-Provera, a widely used birth control shot made by Pfizer, alerting patients to a possible risk for a ...

Andexxa is a recombinant modified human factor Xa protein that received accelerated approval in 2018 for reversal of anticoagulation with rivaroxaban or apixaban due to life-threatening or ...